Short Interest in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Increases By 11.0%

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) was the target of a large growth in short interest during the month of November. As of November 30th, there was short interest totalling 272,100 shares, a growth of 11.0% from the November 15th total of 245,200 shares. Based on an average daily volume of 348,600 shares, the short-interest ratio is presently 0.8 days. Approximately 0.9% of the shares of the company are short sold.

Coeptis Therapeutics Stock Performance

Shares of NASDAQ COEP opened at $0.19 on Tuesday. Coeptis Therapeutics has a one year low of $0.15 and a one year high of $0.97. The company has a current ratio of 0.40, a quick ratio of 0.40 and a debt-to-equity ratio of 0.03. The business has a fifty day simple moving average of $0.20 and a 200 day simple moving average of $0.22. The firm has a market capitalization of $7.85 million, a price-to-earnings ratio of -0.66 and a beta of -0.90.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.